Search
Pepsin
go.drugbank.com/drugs/DB13198ApprovedWithdrawnInterestingly, it has been used as a marker for laryngopharyngeal reflux (LPR), which is a common illness of otolaryngology (ear, nose and throat specialist) visits [A32604]. … Many causes of pancreatic insufficiency require that enzyme replacement therapy is started, including cystic fibrosis, pancreatic cancer, acute and chronic pancreatitis, as well as pancreatic surgery [
Esculin
go.drugbank.com/drugs/DB13155ApprovedEsculin is found in barley. Vitamin C2 is generally considered a bioflavanoid, related to vitamin P esculin is a glucoside that naturally occurs in the horse chestnut (Aesculus hippocastanum), California Buckeye (Aesculus californica) an...
Exenatide
go.drugbank.com/drugs/DB01276ApprovedInvestigationalExenatide was given FDA approval on April 28, 2005[L6106]. It is available as immediate- and extended-release formulations. … [L42685,L42690] Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021.
Sevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigational[L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608] … [L54638] Sevabertinib functions as a reversible kinase inhibitor of human epidermal growth factor receptor 2 (HER2), also exhibiting activity against epidermal growth factor receptor (EGFR).
Avobenzone
go.drugbank.com/drugs/DB09495ApprovedInvestigationalAvobenzone has the ability to absorb ultraviolet light over wider range of wavelengths. It is included in many commercially available sunscreens which are used as wide spectrum sunscreens. … Avobenzone has an absorption maximum of 357 nm. Sunscreens containing avobenzone is indicated for providing protection from the sun.
Mixtures: CARROT SUN SPF30 PA Plus Plus, Lovely Me:ex Bb Cream SPF 20/pa++Isotretinoin
go.drugbank.com/drugs/DB00982ApprovedInvestigational[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. … [L6579] The first isotretinoin-containing product was FDA approved on 7 May 1982.[L6574]
Iptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigational[A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH. … Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor
Genistein
go.drugbank.com/drugs/DB01645InvestigationalExperimentally, it has been shown to induce G2 phase arrest in human and murine cell lines. Additionally, genistein has antihelmintic activity. … It has been investigated in clinical trials as an alternative to classical hormone therapy to help prevent cardiovascular disease in postmenopausal women [A14417].
Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[A189207] Ubrogepant was approved by Health Canada on November 10, 2022. … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.
Clorazepic acid
go.drugbank.com/drugs/DB00628ApprovedIllicitIn September 2020, a black box warning describing these risks was included on the product label of benzodiazepines as per FDA regulation.